Deregulating iron-erythropoiesis regulation: transferrin receptor 2 as potential target for treating anemia in CKD

Kidney Int. 2023 Jul;104(1):25-28. doi: 10.1016/j.kint.2023.04.017.


Both insufficient kidney production of erythropoietin and inflammation-mediated reduction of transferrin-bound iron are major factors in anemia of chronic kidney disease. Improved therapies for anemia in chronic kidney disease may involve modifying regulators of erythropoiesis and iron availability. Olivari et al. show in a mouse model of chronic kidney disease that transferrin receptor 2 in hepatocytes, where it is required for hepcidin production, and in erythroid cells, where it downregulates erythropoietin receptor activity, is a potential therapeutic target.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • Anemia* / drug therapy
  • Anemia* / etiology
  • Animals
  • Erythropoiesis
  • Erythropoietin* / metabolism
  • Erythropoietin* / therapeutic use
  • Hepcidins / metabolism
  • Iron / metabolism
  • Mice
  • Receptors, Transferrin
  • Renal Insufficiency, Chronic* / complications


  • Erythropoietin
  • Hepcidins
  • Iron
  • Receptors, Transferrin
  • TFR2 protein, mouse